Oxtellar Xr is a drug owned by Supernus Pharmaceuticals Inc. It is protected by 11 US drug patents filed from 2013 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2027. Details of Oxtellar Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10220042 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US9119791 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US7910131 | Method of treating seizures using modified release formulations of oxcarbazepine |
Apr, 2027
(1 year, 11 months from now) | Active |
| US11896599 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US11166960 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US9855278 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US9370525 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US8821930 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US8617600 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
| US9351975 | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(1 year, 11 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxtellar Xr's patents.
Latest Legal Activities on Oxtellar Xr's Patents
Given below is the list of recent legal activities going on the following patents of Oxtellar Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 13 Feb, 2024 | US11896599 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Feb, 2024 | US11896599 |
| Recordation of Patent Grant Mailed Critical | 13 Feb, 2024 | US11896599 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896599 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896599 |
| Email Notification Critical | 13 Feb, 2024 | US11896599 |
| Email Notification Critical | 25 Jan, 2024 | US11896599 |
| Issue Notification Mailed Critical | 24 Jan, 2024 | US11896599 |
| Application Is Considered Ready for Issue Critical | 16 Jan, 2024 | US11896599 |
| Dispatch to FDC | 16 Jan, 2024 | US11896599 |
FDA has granted several exclusivities to Oxtellar Xr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Oxtellar Xr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Oxtellar Xr.
Exclusivity Information
Oxtellar Xr holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Oxtellar Xr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 19, 2015 |
US patents provide insights into the exclusivity only within the United States, but Oxtellar Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxtellar Xr's family patents as well as insights into ongoing legal events on those patents.
Oxtellar Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oxtellar Xr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 13, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oxtellar Xr Generic API suppliers:
Oxcarbazepine is the generic name for the brand Oxtellar Xr. 23 different companies have already filed for the generic of Oxtellar Xr, with Rubicon having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Oxtellar Xr's generic
How can I launch a generic of Oxtellar Xr before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Oxtellar Xr's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Oxtellar Xr's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Oxtellar Xr -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 600 mg | 20 Mar, 2013 | 1 | 13 Apr, 2027 | Extinguished | |
| 150 mg and 300 mg | 12 Apr, 2013 | 1 | 13 Apr, 2027 | Extinguished |
Alternative Brands for Oxtellar Xr
Oxtellar Xr which is used for managing partial-onset seizures., has several other brand drugs in the same treatment category and using the same active ingredient (Oxcarbazepine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Sumitomo Pharma Am |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Oxcarbazepine. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxcarbazepine, Oxtellar Xr's active ingredient. Check the complete list of approved generic manufacturers for Oxtellar Xr
About Oxtellar Xr
Oxtellar Xr is a drug owned by Supernus Pharmaceuticals Inc. It is used for managing partial-onset seizures. Oxtellar Xr uses Oxcarbazepine as an active ingredient. Oxtellar Xr was launched by Supernus Pharms in 2012.
Approval Date:
Oxtellar Xr was approved by FDA for market use on 19 October, 2012.
Active Ingredient:
Oxtellar Xr uses Oxcarbazepine as the active ingredient. Check out other Drugs and Companies using Oxcarbazepine ingredient
Treatment:
Oxtellar Xr is used for managing partial-onset seizures.
Dosage:
Oxtellar Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 600MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 300MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |